Delivery Order SPE2DR25D2002-SPE2DR26FBSW2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,848.25 to AmerisourceBergen Drug Corp for IPOL vial 5ML on November 13, 2025, with completion targeted for November 14, 2025. This firm fixed price delivery order was not set-aside and represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $2,159.48 to AmerisourceBergen Drug Corp for IPOL Vial 5ML on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. IPOL is an inactivated poliovirus vaccine commonly used in federal immunization programs and military healthcare systems. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,677.88 to AmerisourceBergen Drug Corp for the supply of IPOL Vial 5ML pharmaceutical products. This firm fixed-price, competitively awarded delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating AmerisourceBergen Drug Corp...
- The Defense Logistics Agency awarded a delivery order valued at $17,441.60 to AmerisourceBergen Drug Corp for IPOL Vial 5ML, an inactivated polio vaccine product. Issued on April 24, 2025, with completion scheduled for April 25, 2025, this firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,834.26 to AmerisourceBergen Drug Corp for IPOL vials (5 mL) on May 27, 2025, with an ultimate completion date of May 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. IPOL is an inactivated polio vaccine used by military and federal healthcare systems to support immunization...
- The Defense Logistics Agency awarded a $52,665.29 delivery order to AmerisourceBergen Drug Corp for IPOL vials in 5ml quantities, with performance in Conshohocken, Pennsylvania and completion targeted for December 24, 2025. This is a firm fixed-price delivery order issued with no set-aside designation, indicating competitive award to this established pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,090.10 to AmerisourceBergen Drug Corp for IPOL vial 5ML, an inactivated polio vaccine product. The contract is a firm fixed price delivery order with an ultimate completion date of October 29, 2025, and represents a non-set-aside competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $10,413.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for IPOL Vial 5ML, a polio vaccine product. This non-set-aside award was issued on December 1, 2025, with an ultimate completion date of December 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $54,368.42 to AmerisourceBergen Drug Corp for the supply of IPOL vial 5ML, a poliomyelitis vaccine product. This firm fixed price, competitively awarded delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader...
- This delivery order, valued at $72,979.90 with an ultimate completion date of November 3, 2025, was awarded by the Defense Logistics Agency to AmerisourceBergen Drug Corp for the supply of IPOL Vial 5ML, a polio vaccine product. The contract employs firm fixed pricing and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location in...
- SPE2DR25D2002Indefinite Delivery Contract
- SPE2DR25D2002-SPE2DR26FBSW2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,037.64 to AmerisourceBergen Drug Corp for IPOL Vial 5ML on December 23, 2025, with completion targeted for December 24, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. IPOL is an inactivated polio vaccine used across military and federal healthcare systems to support immunization programs for service members and beneficiaries. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying vaccines, specialty medications, and medical supplies to support military healthcare programs globally. The award reflects the company's competitive positioning within DLA's pharmaceutical supply chain and its capability to fulfill routine medical supply requirements for federal health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 12/22/25 |